ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / SCTX / insiders
EIKN (43) SABS (38) AGEN (29) IPSC (18) ⌘ Pro Terminal →

Scribe Therapeutics Inc. (SCTX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$15.42 -11.58% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.07

Scribe Therapeutics Inc. (SCTX) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • SELL / AVOID Cap $291.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SCTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SCTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Scribe Therapeutics Inc. (NASDAQ: SCTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $15.42 (-11.58% 1D, market cap $291.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SCTX ranks #409 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SCTX compare to EIKN and SABS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCTX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EIKN (Eikon Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $287.6M) and SABS (SAB Biotherapeutics Inc.) posts a D- grade (38/100 RQD, P/E 22.1x, ROIC -27.4%, cap $304.8M). Among the 5-stock peer group, SABS leads on earnings multiple (22.1x) while IPSC leads on capital efficiency (-14.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SCTX?
▼

Per SCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001853921), Scribe Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $78.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $15.07 (-2.27%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510043
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (10)Whales (3)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-6.7% Base Target
$42 Bull$14 Base$11 Bear
📬 FREE SCTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SCTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY SCTX SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0.2% FCF Margin ($8.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
51
Grade C-$19.12+3.6% Next Q
Q2 (-2Q)
48
Grade D$19.81-19.4% Next Q
Q3 (-1Q)
46
Grade D$15.96-3.4% Next Q
Current
43
Grade D-$15.42-6.7% Hist 90D α
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SCTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SCTX currently carries a cautious 43/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.33) and Max Pain ($16.19) forces dealer call-delta covering toward $41.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SCTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SCTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 43%NO 57%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SCTX Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SCTX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SCTX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SCTX)

  • ✓Walkthrough of SCTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SCTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.71%▼ DESCENDING CHANNEL
2026-11-03O $17.44H $17.44L $15.42C $15.42VOL 480.7K
RES: $28.68SUP: $10.15SMA50: $23.33SMA200: $23.61
$41.43$33.86$26.29$18.72$11.15RES $28.68SUP $10.15$15.422026-07-272026-08-192026-09-152026-10-082026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SCTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SCTX Butterfly Map → + Track SCTX →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SCTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SCTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SCTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SCTX)

Health Care Rank #409 of 1016 ⚔️ EIKN vs SCTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SCTX vs. EIKN, SABS, AGEN, IPSC)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Scribe Therapeutics Inc. (SCTX) ranks #409 by composite RQD confidence (43/100, grade D-) and #520 by equity capitalization ($291.9M). Within this direct 5-issuer industry benchmark cohort, SABS leads on earnings valuation at 22.1x trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. SCTX currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SCTX ACTIVE
Scribe Therapeutics Inc.
D- 43/100 — — — -11.58% $291.9M Benchmark Subject
EIKN
Eikon Therapeutics Inc.
D- 43/100 — — — -0.75% $287.6M /eikn-vs-sctx →
SABS
SAB Biotherapeutics Inc.
D- 38/100 22.1x — -27.4% +3.72% $304.8M /sabs-vs-sctx →
AGEN
Agenus Inc.
E 29/100 — 96.0% -35.0% -3.53% $308.9M /agen-vs-sctx →
IPSC
Century Therapeutics Inc.
E 18/100 — — -14.1% +0.69% $266.2M /ipsc-vs-sctx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001853921

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scribe Therapeutics Inc. (SCTX) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, SCTX closed FY2025 with $78.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 $0 — — $78.2M —

3. SCTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SCTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Scribe Therapeutics Inc. (NASDAQ: SCTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $15.42 (-11.58% 1D, market cap $291.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SCTX ranks #409 in composite RQD confidence.

How does SCTX compare to EIKN and SABS in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCTX carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EIKN (Eikon Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $287.6M) and SABS (SAB Biotherapeutics Inc.) posts a D- grade (38/100 RQD, P/E 22.1x, ROIC -27.4%, cap $304.8M). Among the 5-stock peer group, SABS leads on earnings multiple (22.1x) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SCTX?

Per SCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001853921), Scribe Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $78.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SCTX trading relative to its 50-day, 200-day, and 52-week technical levels?

SCTX last traded at $15.42 (-11.58% on volume of 480,742 shares), positioning the stock -33.90% below its 50-day simple moving average ($23.33) and -34.69% below its 200-day simple moving average ($23.61). Across its 52-week range of $13.50 to $39.60, SCTX sits at the 7.4% percentile with a 14-day RSI of 39.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.49 to $17.35).

SCTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are SCTX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SCTX leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: SCTX RQD Cockpit SCTX 12M Forecast SCTX Earnings & Move SCTX Dividends & DRIP SCTX Insiders & 13F SCTX Whale Options SCTX Profit Sankey SCTX News & Why
ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SCTX — Scribe Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:16:36Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SCTX scores 44 out of 100, earning a letter grade of D and the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine 10/20 (ROIC 0%; FCF yield 0%); Whale 13F Flow 3/20 (institutional accumulation and options positioning); Insider Conviction 9/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 9/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillar is institutional flow at 3/20, followed by the cash engine and macro fit, which signal limited near-term upside support from fundamentals or ownership momentum. The strongest pillar is the forensic balance sheet, where the Altman Z of 2.5 and Piotroski F of 6/9 indicate a comparatively sturdier structure than the cash-generation metrics. For a prospective investor, the rating suggests that the current price of $17.44 is not supported by reported cash generation, which is zero in both ROIC and FCF yield, so any upside case must rest on developments outside the reported financial base. Valuation cannot be assessed on earnings, since P/E and EV/EBITDA are not available in source data. The rating is an analytical summary, not a recommendation.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025 (filed 2025-12-31)$0.0M$0.0M$0.0MN/AN/A$12.8MN/A

Per the SEC financials, the company reported no revenue, operating income, or net income for FY 2025, and gross, operating, and net margins are each 0% per the market data. ROIC is 0% and FCF yield is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 6/9, and Debt/Equity is 0.5, though the financials table lists debt as N/A. Reported cash is $12.8M.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, five items reference SCTX. The most recent is a Yahoo! Finance Canada report (1h ago) tagged as a market wire item. A Seeking Alpha piece titled "Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst" (3h ago) flags a near-term catalyst, though its specifics are not in source data. A MarketBeat item (9h ago) reports significant growth in short interest and is the only item tagged CATALYST with a GREEN signal. A TradingView report (15h ago) notes that Cathie Wood's fund trimmed a holding in a biotech name, but the source data does not confirm SCTX is that name. Risk watch items include rising short interest and the absence of reported revenue or cash flow. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded, with supply chain marked NONE.

Open Questions

  • What are SCTX's specific products, clinical or commercial milestones, and revenue model, given that FY 2025 revenue is reported as $0.0M?
  • What is the debt position, since the financials list debt as N/A while the rating cites Debt/Equity of 0.5?
  • What is the "near-term catalyst" referenced in the Seeking Alpha item, and what is its timing?
  • How much of the 52-week range ($13.5 - $39.6) reflects the current price relative to its trend, and what drove the decline from the high?
  • What is the current cash runway, given reported cash of $12.8M against zero reported revenue and cash flow?

SCTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Scribe Therapeutics Inc. (SCTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SCTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SCTX Bull vs. Bear Conversation Board — What's Your Call at $15.42?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SCTX 🐻 67% BEARISH CONVICTION
1. Pick Your Side on SCTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $15.35 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SCTX (D • RQD 44/100) a Buy at $17.44?

Welcome to the SCTX (Scribe Therapeutics Inc.) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $14.65 (-16.0%)
Spot @ $17.44

Pump the brakes on SCTX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SCTX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Scribe Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $21.63 (+24.0%)
Spot @ $17.44

SCTX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SCTX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $17.44 (52-wk range $13.50 - $39.60), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%